NCATS appreciates the extensive input from its staff, the NCATS Advisory Council, the Cures Acceleration Network Review Board, and members of the translational science community in the development of this strategic plan. In particular, NCATS would like to thank the members of the Strategic Plan Working Group for leading the development of this plan: Penny Burgoon, Christine Cutillo, C. Taylor Gilliland, Cindy McConnell and Dorit Zuk.
-
Research
-
- Funding & Notices
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- A Translational Approach to Addressing COVID-19
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes
- National COVID Cohort Collaborative (N3C)
- NIH Common Fund Programs
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Functional Genomics Lab
- Therapeutics for Rare and Neglected Diseases (TRND)
- About NCATS
- Home
- About NCATS
- Center Overview
- NCATS Strategic Plan
- Strategic Plan Acknowledgments
Strategic Plan Acknowledgments
- Funding & Notices
-